Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 with or without osimertinib in advanced NSCLC
NCT05880706Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2023
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Jul 2023; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05880706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880706.